FOLR1 and ovarian carcinoma: Predominantly expressed in epithelial-derived tumors like ovarian, breast, and lung cancers, FRα's overexpression in 76%−89% of epithelial ovarian cancers, especially absent in normal tissues, positions it as an optimal therapeutic target [9].